Research programme: pathfinder cell therapies - Pathfinder Cell Therapy

Drug Profile

Research programme: pathfinder cell therapies - Pathfinder Cell Therapy

Latest Information Update: 05 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pathfinder Cell Therapy
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Diabetes mellitus; Ischaemia; Osteoarthritis; Reperfusion injury

Most Recent Events

  • 02 Apr 2013 Preclinical pharmacodynamics data from a murine model of Renal ischaemia/reperfusion injury released by Pathfinder Cell Therapy
  • 28 May 2012 Preclinical development in diabetes, cardiac ischaemia and renal reperfusion injury is ongoing in USA
  • 13 Dec 2011 Preclinical trials in Osteoarthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top